Response to fremanezumab for preventive treatment in migraine in routine clinical practice: First data from the FINESSE study

被引：0
|
作者：
Straube, A. [1 ]
Broessner, G. [2 ]
Gaul, C. [3 ]
Hamann, X. [4 ]
Kraya, T. [5 ]
Schaurete, I [6 ]
Carr, K. [7 ]
Neeb, L. [8 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Neurol, Munich, Germany
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Headache Ctr Frankfurt, Frankfurt, Germany
[4] Teva GmbH, Ulm, Germany
[5] St Georg Hosp, Dept Neurol, Leipzig, Germany
[6] Inst Dr Schauerte, Munich, Germany
[7] Teva Pharmaceut, Parsippany, NJ USA
[8] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-194
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [1] Fremanezumab for Preventive Treatment in Migraine: The FINESSE Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Kraya, Torsten
    Schauerte, Isabel
    Neeb, Lars
    [J]. NEUROLOGY, 2022, 98 (18)
  • [2] FINESSE: Fremanezumab for Preventive Treatment in Migraine
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Kraya, T.
    Schauerte, I.
    Neeb, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 117 - 117
  • [3] FINESSE: Fremanezumab for Preventive Treatment in Migraine
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Kraya, T.
    Schauerte, I.
    Neeb, L.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 174 - 175
  • [4] Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
    Ashina, M.
    Mitsikostas, D.
    Amin, F. M.
    Kokturk, P.
    Poole, A. C.
    Sahin, G.
    Schankin, C.
    Nezadal, T.
    Pavao Martins, I.
    Pozo-Rosich, P.
    Dorman, P.
    Sumelahti, M. L.
    Lyras, L.
    Tassorelli, C.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [5] Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study
    Schankin, C.
    Broessner, G.
    Gaul, C.
    Kraya, T.
    Hamann, X.
    Haertel, B.
    Neeb, L.
    Straube, A.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [6] Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study
    Schankin, Christoph
    Broessner, Gregor
    Gaul, Charly
    Kraya, Torsten
    Hamann, Xenia
    Haertel, Birgit
    Neeb, Lars
    Straube, Andreas
    [J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 13 - 14
  • [7] Fremanezumab Effectiveness and Tolerability in Clinical Routine: Interim Real-World-Data of the Observational FINESSE Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Kraya, Torsten
    Neeb, Lars
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 243 - 244
  • [8] Fremanezumab effectiveness and tolerability in clinical routine: interim real-world-data of the observational FINESSE study
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Kraya, T.
    Neeb, L.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [9] Effectiveness of fremanezumab for preventive treatment of migraine: the observational PEARL study
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Poole, A.
    Sahin, G.
    Schankin, C.
    Nezadal, T.
    Lyras, L.
    Ning, X.
    Krasenbaum, L.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 192 - 193
  • [10] Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
    Pazdera, Ladislav
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Yang, Ronghua
    Pozo-Rosich, Patricia
    [J]. CEPHALALGIA, 2021, 41 (10) : 1075 - 1088
12345